Welcome to our dedicated page for Bio-Rad Laboratories news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio-Rad Laboratories stock.
Bio-Rad Laboratories, Inc. reports news on its life science research and clinical diagnostics products, including instruments, reagents, test systems, specialized quality controls, blood typing, diabetes products, infectious disease products, and Droplet Digital PCR technologies.
Company updates commonly cover quarterly and annual financial results, Clinical Diagnostics and Life Science segment trends, currency and end-market conditions, product portfolio developments, share repurchases, earnings calls, and healthcare investor conferences. Bio-Rad’s customer base includes universities, research institutions, hospitals, biopharmaceutical companies, and clinical, food safety, and environmental quality laboratories.
Bio-Rad (NYSE: BIO, BIO.B) announced that Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat at Wells Fargo’s 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM ET (12:45 PM PT). A live webcast and replay will be accessible via the Investor Relations section of Bio-Rad’s website at investors.bio-rad.com.
Insight Molecular Diagnostics (Nasdaq: IMDX) reported Q2 2026 revenue of approximately $239,000, largely from laboratory services, plus $21,000 from research-use-only kits, and gross profit of $157,000, a 65.7% gross margin. Net loss was $11.3 million, or $0.31 per share, and adjusted net loss was $8.3 million, or $0.23 per share.
Operating expenses were $11.6 million, including $2.3 million non-cash contingent consideration, $661,000 stock-based compensation, and $641,000 depreciation and amortization. Non-GAAP operating expenses decreased 13% sequentially but rose 26% year over year. Adjusted EBITDA loss was $7.8 million. IMDX ended Q2 with $18.7 million in cash, cash equivalents and restricted cash and outgoing free cash flow of about $10 million.
The company highlighted timely FDA review progress for its GraftAssureDx kidney transplant test kit, favorable Medicare reimbursement changes for dd-cfDNA surveillance and treatment-response monitoring, and multiple peer-reviewed clinical studies showing strong performance and head-to-head analytical data for GraftAssure.
Bio-Rad (NYSE: BIO) reported Q2 2026 net sales of $651.0 million, essentially flat versus Q2 2025’s $651.6 million; currency-neutral sales declined 1.9%, driven by lower Life Science revenue. GAAP gross margin was 53.1% and non-GAAP gross margin 53.9%.
Life Science segment sales were $252.0 million, down 4.1% (5.1% currency-neutral), while Clinical Diagnostics sales were $399.0 million, up 2.6% (0.3% currency-neutral). GAAP income from operations was $72.6 million versus $77.1 million a year ago.
Helped largely by a change in the fair value of its Sartorius AG investment, Bio-Rad reported Q2 GAAP net income of $371.4 million or $13.85 per diluted share. Non-GAAP net income was $70.2 million or $2.62 per diluted share. Operating cash flow was $98.7 million, and the company repurchased about $32 million of shares. For full-year 2026, Bio-Rad reaffirmed guidance for non-GAAP, currency-neutral revenue ranging from a 3.0% decline to 0.5% growth and a non-GAAP operating margin of 10.0–12.0%, according to the company.
Bio-Rad (NYSE: BIO, BIO.B) announced it will report its second-quarter 2026 financial results on Tuesday, August 4, 2026, after the market close. Company management will host a conference call at 2:00 PM Pacific Time (5:00 PM Eastern Time) the same day to discuss the results.
Investors can join the call by dialing (800) 715-9871 in the U.S. or (646) 307-1963 internationally, with access code 9562470. A live webcast will be available in the Investor Relations > Events & Presentations section at investors.bio-rad.com, and a replay of the webcast will remain accessible for up to one year.
Bio-Rad (NYSE: BIO) will participate in two investor conferences in May–June 2026, with CFO Roop K. Lakkaraju hosting fireside chats and one-on-one investor meetings.
Events: RBC Capital Markets Global Healthcare Conference on May 19, 2026 at 8:30 AM ET, and Jefferies Global Healthcare Conference on June 3, 2026 at 8:45 AM ET. Live webcasts and replays will be available in the Investor Relations section at bio-rad.com.
Bio-Rad (NYSE: BIO) reported Q1 2026 results: net sales $592.1M (+1.1% YoY; currency-neutral -4.2%). GAAP net loss was $527.1M due to a fair-value change in a Sartorius AG investment; non-GAAP net income was $50.9M and free cash flow was $78.1M. The company updated 2026 non-GAAP guidance to currency-neutral revenue -3.0% to +0.5% and estimated non-GAAP operating margin ~10.0–12.0%.
Bio-Rad (NYSE: BIO) will report first-quarter 2026 financial results on Thursday, April 30, 2026 following market close. Management will hold a conference call at 2:00 PM Pacific / 5:00 PM Eastern that day with dial-in access and a live webcast.
Dial-in numbers and access code are provided, and a webcast replay will be available for up to one year in the company’s Investor Relations "Events & Presentations" section.
Bio-Rad (NYSE: BIO) reported Q4 2025 net sales of $693.2M (+3.9% YoY) and full‑year 2025 revenue of $2,583.2M (+0.7% YoY). Non‑GAAP net income was $270.5M or $9.92 per diluted share; GAAP net income benefited from a fair‑value gain tied to Sartorius AG, producing GAAP net income of $759.9M.
The company recorded a $172.8M impairment of purchased intangibles, generated $532M cash from operations and $375M free cash flow, completed integration of Stilla for expanded ddPCR offerings, and provided 2026 non‑GAAP guidance of ~0.5–1.5% currency‑neutral revenue growth and ~12.0–12.5% non‑GAAP operating margin.
Bio-Rad (NYSE: BIO) will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026 after market close. Management will host a conference call at 2:00 PM PT / 5:00 PM ET to discuss results.
To join, dial domestic or international numbers with access code 9562470, or use the live webcast and supplemental presentation in the Investor Relations "Events & Presentations" section. A replay will be available for up to one year.
Bio-Rad (NYSE: BIO / BIO.B) said its CEO Norman Schwartz, COO Jon DiVincenzo, and CFO Roop K. Lakkaraju will hold one-on-one meetings with analysts and investors at J.P. Morgan's 44th Annual Healthcare Conference in San Francisco, CA, January 12–15, 2026.
The meetings are scheduled as part of the company's participation in the conference and are intended to provide investor engagement and updates on corporate strategy and operations.